So true BMS! Financial Conundrum V. Product Fai
Post# of 30066
Posted On: 03/17/2016 10:52:13 PM
So true BMS!
Financial Conundrum V. Product Failures
That's where we are at present. I would much rather have a bit of a hurdle to climb financially than a Product Failure.
One you can overcome, the other you cannot.
So far nothing in the TX side nor the new DX company has shown any signs of failing.s
It only takes one. And with the amount of "shots on goal" I personally like the ODD's (pun intended)
TheraLink® Assay includes phospho-activation markers for known drug targets of over 30 approved molecular targeted therapies for treating breast cancer patients. In addition, the TheraLink® Assay panel includes other biomarkers that have utility in directing patients to clinical trials involving new investigational agents. Research programs and clinical trials are underway at leading institutions to validate the TheraLink® Assay panel for managing cancer treatment decision-making in other clinically significant areas such as colorectal, lung, pancreatic and ovarian cancer.
LymPro - ALZ IUO Approved
LymPro - ALZ Agression
LymPro - CTE
OvaDx - O.C.
MSPrecise - M.S.
MSPrecise - N.O.
ESS – Severe Adult Burns ODD Granted
ESS - SeverePediatric Burns ODD Granted
ESS – Congenital Giant Hairy Nevus ODD pending decision
ELTO - PD LID ODD Granted
ELTO – ADHD
ELTO – AD Aggression
MANF – Retinitis Pigmentosa ODD - Granted
MANF – Retinal Artery Occlusion ODD - Granted
MANF – Retinitis Pigmentosa EMA ODD - Granted
RPDD - pending approval
ESS in the treatment of Giant Congenital Hairy Nevus
ESS in the treatment of Severe Pediatric Burns
MANF in the treatment of RP
Trials
ESS
1 Phase II Adult severe burns - Slated for April
2 Phase III's Pediatric severe burns & Giant Congenital Melanocytic Nevi (GCMN):
ELTOP - PD LID ODD
Phase IIb - evaluating expedited pathways to market for eltoprazine that may now be afforded by the orphan drug designation ."
Revenue generating CLIA laboratory
Cheers
Financial Conundrum V. Product Failures
That's where we are at present. I would much rather have a bit of a hurdle to climb financially than a Product Failure.
One you can overcome, the other you cannot.
So far nothing in the TX side nor the new DX company has shown any signs of failing.s
It only takes one. And with the amount of "shots on goal" I personally like the ODD's (pun intended)
TheraLink® Assay includes phospho-activation markers for known drug targets of over 30 approved molecular targeted therapies for treating breast cancer patients. In addition, the TheraLink® Assay panel includes other biomarkers that have utility in directing patients to clinical trials involving new investigational agents. Research programs and clinical trials are underway at leading institutions to validate the TheraLink® Assay panel for managing cancer treatment decision-making in other clinically significant areas such as colorectal, lung, pancreatic and ovarian cancer.
LymPro - ALZ IUO Approved
LymPro - ALZ Agression
LymPro - CTE
OvaDx - O.C.
MSPrecise - M.S.
MSPrecise - N.O.
ESS – Severe Adult Burns ODD Granted
ESS - SeverePediatric Burns ODD Granted
ESS – Congenital Giant Hairy Nevus ODD pending decision
ELTO - PD LID ODD Granted
ELTO – ADHD
ELTO – AD Aggression
MANF – Retinitis Pigmentosa ODD - Granted
MANF – Retinal Artery Occlusion ODD - Granted
MANF – Retinitis Pigmentosa EMA ODD - Granted
RPDD - pending approval
ESS in the treatment of Giant Congenital Hairy Nevus
ESS in the treatment of Severe Pediatric Burns
MANF in the treatment of RP
Trials
ESS
1 Phase II Adult severe burns - Slated for April
2 Phase III's Pediatric severe burns & Giant Congenital Melanocytic Nevi (GCMN):
ELTOP - PD LID ODD
Phase IIb - evaluating expedited pathways to market for eltoprazine that may now be afforded by the orphan drug designation ."
Revenue generating CLIA laboratory
Cheers
(9)
(1)